Below you will find HOPA positions as expressed in policy briefs, policy statements, and letters. HOPA

HOPA Issues Principles of Health Reform

View the issue brief on HOPA Health Reform Principles.

Issues Statement on First Approved Biosimilar in the United States

HOPA is encouraged by the Food and Drug Administration's (FDA) approval of the first biosimilar product, Zarxio (filgrastim-sndz), in the United States, but strongly urges the FDA to develop a naming policy for approved biosimilars.

View the HOPA Biosimilars Issue Brief, or read the ONS press release regarding the meeting of Safe Handling of Hazardous Drugs Association Stakeholders.

HOPA Joins ONS and ASCO in Joint Position Statement

HOPA has been working with ONS and ASCO on a joint position statement entitled, "Ensuring Healthcare Worker Safety When Handling Hazardous Drugs." The intent of this document is to ensure that there are policies and procedures in place to safeguard healthcare workers as well as their patients and minimize exposure risk when handling hazardous drugs. HOPA would like to thank Niesha Griffith, Dana McCauley, and Ray Mueller for their work in developing the statement.